ncRNA basic information
ncRNA ID:
MIMAT0000267
ncRNA Database:
miRBase
ncRNA Name:
miR-210-3p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
E2F3
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The potential role of microRNA (miR)-210-3p in carcinogenesis and the cisplatin sensitivity of ovarian cancer were evaluated in the present study. The relative expression levels of miR-210-3p in cisplatin-sensitive SKOV-3 cells and cisplatin-resistant SKOV-3/DDP cells were determined using reverse transcription-quantitative polymerase chain reaction analysis. miR-210-3p mimics and inhibitors were transfected into SKOV-3/DDP cells. Cell Counting Kit-8, scratch and Transwell invasion assays and flow cytometry were conducted to evaluate the role of miR-210-3p in ovarian cancer cells. A luciferase reporter assay was used to verify the association between miR-210-3p and E2F transcription factor 3 (E2F3). Drug sensitivity was evaluated by treating the cells with cisplatin.
Drug Response:
sensitive
Cancer basic information
Cancer:
ovarian cancer
Tissue/Cell:
cell line (SKOV-3,SKOV-3/DDP)
Other information
Title:
miR-210-3p regulates cell growth and affects cisplatin sensitivity in human ovarian cancer cells via targeting E2F3.
Journal:
Mol Med Rep
Published:
2019
PubMed ID:
30957179